Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Academic Productivity of US Neurosurgery Residents as Measured by H-Index: Program Ranking with Correlation to Faculty Productivity.

Sarkiss CA, Riley KJ, Hernandez CM, Oermann EK, Ladner TR, Bederson JB, Shrivastava RK.

Neurosurgery. 2017 Jun 1;80(6):975-984. doi: 10.1093/neuros/nyx071.

PMID:
28368531
2.

Epstein-Barr viral microRNAs target caspase 3.

Harold C, Cox D, Riley KJ.

Virol J. 2016 Aug 26;13:145. doi: 10.1186/s12985-016-0602-7.

3.

Evaluation of TK1 targeting carboranyl thymidine analogs as potential delivery agents for neutron capture therapy of brain tumors.

Barth RF, Yang W, Nakkula RJ, Byun Y, Tjarks W, Wu LC, Binns PJ, Riley KJ.

Appl Radiat Isot. 2015 Dec;106:251-5. doi: 10.1016/j.apradiso.2015.06.031. Epub 2015 Jul 2.

4.

Alternative capture of noncoding RNAs or protein-coding genes by herpesviruses to alter host T cell function.

Guo YE, Riley KJ, Iwasaki A, Steitz JA.

Mol Cell. 2014 Apr 10;54(1):67-79. doi: 10.1016/j.molcel.2014.03.025.

5.

Adiponectin regulates bone mass via opposite central and peripheral mechanisms through FoxO1.

Kajimura D, Lee HW, Riley KJ, Arteaga-Solis E, Ferron M, Zhou B, Clarke CJ, Hannun YA, DePinho RA, Guo XE, Mann JJ, Karsenty G.

Cell Metab. 2013 Jun 4;17(6):901-15. doi: 10.1016/j.cmet.2013.04.009. Epub 2013 May 16. Erratum in: Cell Metab. 2014 May 6;19(5):891. Guo, Edward X [corrected to Guo, X Edward].

6.

The "Observer Effect" in genome-wide surveys of protein-RNA interactions.

Riley KJ, Steitz JA.

Mol Cell. 2013 Feb 21;49(4):601-4. doi: 10.1016/j.molcel.2013.01.030. Review.

7.

Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer.

Barth RF, Vicente MG, Harling OK, Kiger WS 3rd, Riley KJ, Binns PJ, Wagner FM, Suzuki M, Aihara T, Kato I, Kawabata S.

Radiat Oncol. 2012 Aug 29;7:146. doi: 10.1186/1748-717X-7-146. Review.

8.

Treatment length and outcomes among adolescents: a secondary data analysis.

Riley KJ, Srikanth P, Choi D, McCarty D.

Subst Abuse Treat Prev Policy. 2012 Aug 16;7:35. doi: 10.1186/1747-597X-7-35.

9.

Association of Argonaute proteins and microRNAs can occur after cell lysis.

Riley KJ, Yario TA, Steitz JA.

RNA. 2012 Sep;18(9):1581-5. doi: 10.1261/rna.034934.112. Epub 2012 Jul 26.

10.

EBV and human microRNAs co-target oncogenic and apoptotic viral and human genes during latency.

Riley KJ, Rabinowitz GS, Yario TA, Luna JM, Darnell RB, Steitz JA.

EMBO J. 2012 May 2;31(9):2207-21. doi: 10.1038/emboj.2012.63. Epub 2012 Mar 30.

11.

Comparison of intracerebral delivery of carboplatin and photon irradiation with an optimized regimen for boron neutron capture therapy of the F98 rat glioma.

Barth RF, Yang W, Huo T, Riley KJ, Binns PJ, Grecula JC, Gupta N, Rousseau J, Elleaume H.

Appl Radiat Isot. 2011 Dec;69(12):1813-6. doi: 10.1016/j.apradiso.2011.03.019. Epub 2011 Mar 21.

PMID:
21493080
12.

Genetic determination of the cellular basis of the sympathetic regulation of bone mass accrual.

Kajimura D, Hinoi E, Ferron M, Kode A, Riley KJ, Zhou B, Guo XE, Karsenty G.

J Exp Med. 2011 Apr 11;208(4):841-51. doi: 10.1084/jem.20102608. Epub 2011 Mar 28.

13.

Convection enhanced delivery of carboranylporphyrins for neutron capture therapy of brain tumors.

Kawabata S, Yang W, Barth RF, Wu G, Huo T, Binns PJ, Riley KJ, Ongayi O, Gottumukkala V, Vicente MG.

J Neurooncol. 2011 Jun;103(2):175-85. doi: 10.1007/s11060-010-0376-5. Epub 2010 Sep 17.

14.

Comprehensive analysis of Rhesus lymphocryptovirus microRNA expression.

Riley KJ, Rabinowitz GS, Steitz JA.

J Virol. 2010 May;84(10):5148-57. doi: 10.1128/JVI.00110-10. Epub 2010 Mar 10.

15.

Convection enhanced delivery of boronated EGF as a molecular targeting agent for neutron capture therapy of brain tumors.

Yang W, Barth RF, Wu G, Huo T, Tjarks W, Ciesielski M, Fenstermaker RA, Ross BD, Wikstrand CJ, Riley KJ, Binns PJ.

J Neurooncol. 2009 Dec;95(3):355-365. doi: 10.1007/s11060-009-9945-x. Epub 2009 Jul 9.

16.

An international dosimetry exchange for BNCT part II: computational dosimetry normalizations.

Riley KJ, Binns PJ, Harling OK, Albritton JR, Kiger WS 3rd, Rezaei A, Sköld K, Seppälä T, Savolainen S, Auterinen I, Marek M, Viererbl L, Nievaart VA, Moss RL.

Med Phys. 2008 Dec;35(12):5419-25.

PMID:
19175101
17.

Thymidine kinase 1 as a molecular target for boron neutron capture therapy of brain tumors.

Barth RF, Yang W, Wu G, Swindall M, Byun Y, Narayanasamy S, Tjarks W, Tordoff K, Moeschberger ML, Eriksson S, Binns PJ, Riley KJ.

Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17493-7. doi: 10.1073/pnas.0809569105. Epub 2008 Nov 3.

18.

Functional and histological changes in rat lung after boron neutron capture therapy.

Kiger JL, Kiger WS 3rd, Riley KJ, Binns PJ, Patel H, Hopewell JW, Harling OK, Busse PM, Coderre JA.

Radiat Res. 2008 Jul;170(1):60-9. doi: 10.1667/RR1266.1.

PMID:
18582158
19.

Implementation of MET/CBT 5 for adolescents.

Riley KJ, Rieckmann T, McCarty D.

J Behav Health Serv Res. 2008 Jul;35(3):304-14. doi: 10.1007/s11414-008-9111-9. Epub 2008 May 21.

20.

Unifying dose specification between clinical BNCT centers in the Americas.

Riley KJ, Binns PJ, Harling OK, Kiger WS 3rd, González SJ, Casal MR, Longhino J, Larrieu OA, Blaumann HR.

Med Phys. 2008 Apr;35(4):1295-8.

PMID:
18491523
21.

Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies.

Yang W, Wu G, Barth RF, Swindall MR, Bandyopadhyaya AK, Tjarks W, Tordoff K, Moeschberger M, Sferra TJ, Binns PJ, Riley KJ, Ciesielski MJ, Fenstermaker RA, Wikstrand CJ.

Clin Cancer Res. 2008 Feb 1;14(3):883-91. doi: 10.1158/1078-0432.CCR-07-1968.

22.

Analysis of p53-RNA interactions in cultured human cells.

Riley KJ, James Maher L 3rd.

Biochem Biophys Res Commun. 2007 Nov 16;363(2):381-7. Epub 2007 Sep 10.

23.

p53 RNA interactions: new clues in an old mystery.

Riley KJ, Maher LJ 3rd.

RNA. 2007 Nov;13(11):1825-33. Epub 2007 Sep 5. Review.

24.

Normalisation of prescribed dose in BNCT.

Binns PJ, Riley KJ, Harling OK, Albritton JR, Kiger WS 3rd.

Radiat Prot Dosimetry. 2007;126(1-4):610-4. Epub 2007 May 23.

PMID:
17522033
25.

Process improvement needs in substance abuse treatment: admissions walk-through results.

Ford JH 2nd, Green CA, Hoffman KA, Wisdom JP, Riley KJ, Bergmann L, Molfenter T.

J Subst Abuse Treat. 2007 Dec;33(4):379-89. Epub 2007 May 17.

26.

No significant endothelial apoptosis in the radiation-induced gastrointestinal syndrome.

Schuller BW, Rogers AB, Cormier KS, Riley KJ, Binns PJ, Julius R, Hawthorne MF, Coderre JA.

Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):205-10.

PMID:
17448874
27.

Improved dose targeting for a clinical epithermal neutron capture beam using optional (6)Li filtration.

Binns PJ, Riley KJ, Ostrovsky Y, Gao W, Albritton JR, Kiger WS 3rd, Harling OK.

Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1484-91.

PMID:
17394946
28.

Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab.

Wu G, Yang W, Barth RF, Kawabata S, Swindall M, Bandyopadhyaya AK, Tjarks W, Khorsandi B, Blue TE, Ferketich AK, Yang M, Christoforidis GA, Sferra TJ, Binns PJ, Riley KJ, Ciesielski MJ, Fenstermaker RA.

Clin Cancer Res. 2007 Feb 15;13(4):1260-8.

29.

RNA-p53 interactions in vitro.

Riley KJ, Ramirez-Alvarado M, Maher LJ 3rd.

Biochemistry. 2007 Mar 6;46(9):2480-7. Epub 2007 Feb 9.

PMID:
17288451
30.
31.
32.

Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4.

Yang W, Barth RF, Wu G, Kawabata S, Sferra TJ, Bandyopadhyaya AK, Tjarks W, Ferketich AK, Moeschberger ML, Binns PJ, Riley KJ, Coderre JA, Ciesielski MJ, Fenstermaker RA, Wikstrand CJ.

Clin Cancer Res. 2006 Jun 15;12(12):3792-802.

33.

Recognition of RNA by the p53 tumor suppressor protein in the yeast three-hybrid system.

Riley KJ, Cassiday LA, Kumar A, Maher LJ 3rd.

RNA. 2006 Apr;12(4):620-30.

34.

Selective irradiation of the vascular endothelium has no effect on the survival of murine intestinal crypt stem cells.

Schuller BW, Binns PJ, Riley KJ, Ma L, Hawthorne MF, Coderre JA.

Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3787-92. Epub 2006 Feb 27.

35.

An international dosimetry exchange for boron neutron capture therapy. Part I: Absorbed dose measurements.

Binns PJ, Riley KJ, Harling OK, Kiger WS 3rd, Munck af Rosenschöld PM, Giusti V, Capala J, Sköld K, Auterinen I, Serén T, Kotiluoto P, Uusi-Simola J, Marek M, Viererbl L, Spurny F.

Med Phys. 2005 Dec;32(12):3729-36.

PMID:
16475772
36.

RBE of the MIT epithermal neutron beam for crypt cell regeneration in mice.

Gueulette J, Binns PJ, De Coster BM, Lu XQ, Roberts SA, Riley KJ.

Radiat Res. 2005 Dec;164(6):805-9.

PMID:
16296887
37.

The MIT user center for neutron capture therapy research.

Harling OK, Riley KJ, Binns PJ, Patel H, Coderre JA.

Radiat Res. 2005 Aug;164(2):221-9.

PMID:
16038593
38.
39.

A state-of-the-art epithermal neutron irradiation facility for neutron capture therapy.

Riley KJ, Binns PJ, Harling OK.

Phys Med Biol. 2004 Aug 21;49(16):3725-35.

PMID:
15446801
40.

Dosimetric measurements with a brain equivalent plastic walled ionization chamber in an epithermal neutron beam.

Binns PJ, Riley KJ, Harling OK.

Radiat Prot Dosimetry. 2004;110(1-4):687-92.

PMID:
15353731
41.

Tolerance of normal human brain to boron neutron capture therapy.

Coderre JA, Hopewell JW, Turcotte JC, Riley KJ, Binns PJ, Kiger WS 3rd, Harling OK.

Appl Radiat Isot. 2004 Nov;61(5):1083-7.

PMID:
15308196
42.

Preliminary treatment planning and dosimetry for a clinical trial of neutron capture therapy using a fission converter epithermal neutron beam.

Kiger WS 3rd, Lu XQ, Harling OK, Riley KJ, Binns PJ, Kaplan J, Patel H, Zamenhof RG, Shibata Y, Kaplan ID, Busse PM, Palmer MR.

Appl Radiat Isot. 2004 Nov;61(5):1075-81.

PMID:
15308195
43.

Effects of boron neutron capture irradiation on the normal lung of rats.

Kiger JL, Kiger WS, Patel H, Binns PJ, Riley KJ, Hopewell JW, Harling OK, Coderre JA.

Appl Radiat Isot. 2004 Nov;61(5):969-73.

PMID:
15308177
44.

Neutron capture therapy of epidermal growth factor (+) gliomas using boronated cetuximab (IMC-C225) as a delivery agent.

Barth RF, Wu G, Yang W, Binns PJ, Riley KJ, Patel H, Coderre JA, Tjarks W, Bandyopadhyaya AK, Thirumamagal BT, Ciesielski MJ, Fenstermaker RA.

Appl Radiat Isot. 2004 Nov;61(5):899-903.

PMID:
15308165
45.

Progress with the NCT international dosimetry exchange.

Binns PJ, Riley KJ, Harling OK, Auterinen I, Marek M, Kiger WS 3rd.

Appl Radiat Isot. 2004 Nov;61(5):865-8.

PMID:
15308159
46.

The design, construction and performance of a variable collimator for epithermal neutron capture therapy beams.

Riley KJ, Binns PJ, Ali SJ, Harling OK.

Phys Med Biol. 2004 May 21;49(10):2015-28.

PMID:
15214538
47.

Boron neutron capture therapy: cellular targeting of high linear energy transfer radiation.

Coderre JA, Turcotte JC, Riley KJ, Binns PJ, Harling OK, Kiger WS 3rd.

Technol Cancer Res Treat. 2003 Oct;2(5):355-75. Review.

PMID:
14529302
48.

Pharamacokinetic modeling for boronophenylalanine-fructose mediated neutron capture therapy: 10B concentration predictions and dosimetric consequences.

Kiger WS 3rd, Palmer MR, Riley KJ, Zamenhof RG, Busse PM.

J Neurooncol. 2003 Mar-Apr;62(1-2):171-86.

PMID:
12749712
49.

A critical examination of the results from the Harvard-MIT NCT program phase I clinical trial of neutron capture therapy for intracranial disease.

Busse PM, Harling OK, Palmer MR, Kiger WS 3rd, Kaplan J, Kaplan I, Chuang CF, Goorley JT, Riley KJ, Newton TH, Santa Cruz GA, Lu XQ, Zamenhof RG.

J Neurooncol. 2003 Mar-Apr;62(1-2):111-21.

PMID:
12749707
50.

Fission reactor neutron sources for neutron capture therapy--a critical review.

Harling OK, Riley KJ.

J Neurooncol. 2003 Mar-Apr;62(1-2):7-17. Review.

PMID:
12749699

Supplemental Content

Loading ...
Support Center